Literature DB >> 3342469

Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.

C Fournier1, P Vennin, B Hecquet.   

Abstract

The plasma kinetics of platinum after i.v. bolus administration of cisplatin was determined for 17 patients with advanced cancer. Statistical analysis of individual values revealed a high correlation between the area under the plasma concentration-time curve (AUC) of free platinum (unbound to proteins) and the concentration of platinum bound to plasma proteins 24 h after drug administration (Cp24). A similar correlation was found between the peak plasma values of ultrafiltrable platinum (Cp0) and Cp24. When studied in the same patient, increases in free platinum AUC and Cp0 were also found to result in increased Cp24. It is suggested that a single measurement of plasma platinum concentration 24 h after i.v. infusion of cisplatin could be a simple method either of detecting patients with extreme values of AUC and Cp0 or of studying the evolution of these parameters during multiple courses of treatment, although it cannot be used to give precise values for AUC and Cp0.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3342469     DOI: 10.1007/bf00262745

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

Authors:  A F LeRoy; M L Wehling; H L Sponseller; W S Friauf; R E Solomon; R L Dedrick; C L Litterst; T E Gram; A M Guarino; D A Becker
Journal:  Biochem Med       Date:  1977-10

Review 2.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  In vitro interactions of TNO6 with human plasma.

Authors:  B Hecquet; L Adenis; A Demaille
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

6.  Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1984-10-01       Impact factor: 5.858

7.  Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.

Authors:  A B Campbell; S M Kalman; C Jacobs
Journal:  Cancer Treat Rep       Date:  1983-02

Review 8.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

9.  Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin.

Authors:  K Takahashi; T Seki; K Nishikawa; S Minamide; M Iwabuchi; M Ono; S Nagamine; H Horinishi
Journal:  Jpn J Cancer Res       Date:  1985-01

10.  Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; H E Gall; H M Pinedo
Journal:  Eur J Cancer Clin Oncol       Date:  1982-11
View more
  6 in total

1.  Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

Authors:  Mayur A Gadhikar; Maria Rita Sciuto; Marcus Vinicius Ortega Alves; Curtis R Pickering; Abdullah A Osman; David M Neskey; Mei Zhao; Alison L Fitzgerald; Jeffrey N Myers; Mitchell J Frederick
Journal:  Mol Cancer Ther       Date:  2013-07-09       Impact factor: 6.261

2.  Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.

Authors:  P H Cashin; H Ehrsson; I Wallin; P Nygren; H Mahteme
Journal:  Eur J Clin Pharmacol       Date:  2012-09-16       Impact factor: 2.953

3.  Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Authors:  W P Petros; S G Chaney; D C Smith; J Fangmeier; M Sakata; T D Brown; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.

Authors:  S Ghazal-Aswad; A H Calvert; D R Newell
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 5.  A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.

Authors:  Gabriel W Loh; Lillian S L Ting; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Long-term pharmacokinetic behavior of platinum after cisplatin administration.

Authors:  E Gamelin; P Allain; P Maillart; A Turcant; R Delva; A Lortholary; F Larra
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.